These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

151 related items for PubMed ID: 1394237

  • 1. Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients.
    Foekens JA, Schmitt M, van Putten WL, Peters HA, Bontenbal M, Jänicke F, Klijn JG.
    Cancer Res; 1992 Nov 01; 52(21):6101-5. PubMed ID: 1394237
    [Abstract] [Full Text] [Related]

  • 2. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients.
    Foekens JA, Peters HA, Look MP, Portengen H, Schmitt M, Kramer MD, Brünner N, Jänicke F, Meijer-van Gelder ME, Henzen-Logmans SC, van Putten WL, Klijn JG.
    Cancer Res; 2000 Feb 01; 60(3):636-43. PubMed ID: 10676647
    [Abstract] [Full Text] [Related]

  • 3. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis.
    Grøndahl-Hansen J, Christensen IJ, Rosenquist C, Brünner N, Mouridsen HT, Danø K, Blichert-Toft M.
    Cancer Res; 1993 Jun 01; 53(11):2513-21. PubMed ID: 8388317
    [Abstract] [Full Text] [Related]

  • 4. Prognostic value of p53 and urokinase-type plasminogen activator in node-negative human breast cancers.
    Peyrat JP, Vanlemmens L, Fournier J, Huet G, Révillion F, Bonneterre J.
    Clin Cancer Res; 1998 Jan 01; 4(1):189-96. PubMed ID: 9516970
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Complex of urokinase-type plasminogen activator with its type 1 inhibitor predicts poor outcome in 576 patients with lymph node-negative breast carcinoma.
    Manders P, Tjan-Heijnen VC, Span PN, Grebenchtchikov N, Geurts-Moespot A, van Tienoven DT, Beex LV, Sweep FC.
    Cancer; 2004 Aug 01; 101(3):486-94. PubMed ID: 15274061
    [Abstract] [Full Text] [Related]

  • 9. [Prognostic value of urokinase-type plasminogen activator and 2 inhibitors PAI-1 and PAI-2 in breast cancer].
    Bouchet C, Spyratos F, Martin PM, Hacène K, Gentile A, Oglobine J.
    Bull Cancer; 1994 Sep 01; 81(9):770-9. PubMed ID: 7703566
    [Abstract] [Full Text] [Related]

  • 10. Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer.
    Nekarda H, Schmitt M, Ulm K, Wenninger A, Vogelsang H, Becker K, Roder JD, Fink U, Siewert JR.
    Cancer Res; 1994 Jun 01; 54(11):2900-7. PubMed ID: 8187075
    [Abstract] [Full Text] [Related]

  • 11. Prognostic value of uPA and p53 accumulation measured by quantitative biochemical assays in 1245 primary breast cancer patients: a multicentre study.
    Broët P, Spyratos F, Romain S, Quillien V, Daver A, Ricolleau G, Rallet A, Toulas C, Asselain B.
    Br J Cancer; 1999 May 01; 80(3-4):536-45. PubMed ID: 10408864
    [Abstract] [Full Text] [Related]

  • 12. The prognostic value of polymorphonuclear leukocyte elastase in patients with primary breast cancer.
    Foekens JA, Ries C, Look MP, Gippner-Steppert C, Klijn JG, Jochum M.
    Cancer Res; 2003 Jan 15; 63(2):337-41. PubMed ID: 12543785
    [Abstract] [Full Text] [Related]

  • 13. Multimarker phenotype predicts adverse survival in patients with lymph node-negative colorectal cancer.
    Zlobec I, Minoo P, Baumhoer D, Baker K, Terracciano L, Jass JR, Lugli A.
    Cancer; 2008 Feb 01; 112(3):495-502. PubMed ID: 18076013
    [Abstract] [Full Text] [Related]

  • 14. Plasminogen activator inhibitor-1 and prognosis in primary breast cancer.
    Foekens JA, Schmitt M, van Putten WL, Peters HA, Kramer MD, Jänicke F, Klijn JG.
    J Clin Oncol; 1994 Aug 01; 12(8):1648-58. PubMed ID: 8040677
    [Abstract] [Full Text] [Related]

  • 15. Prognostic impact of urokinase-type plasminogen activator (PA), PA inhibitor type-1, and tissue-type PA antigen levels in node-negative breast cancer: a prospective study on multicenter basis.
    Kim SJ, Shiba E, Kobayashi T, Yayoi E, Furukawa J, Takatsuka Y, Shin E, Koyama H, Inaji H, Takai S.
    Clin Cancer Res; 1998 Jan 01; 4(1):177-82. PubMed ID: 9516968
    [Abstract] [Full Text] [Related]

  • 16. Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type 1.
    Jänicke F, Pache L, Schmitt M, Ulm K, Thomssen C, Prechtl A, Graeff H.
    Cancer Res; 1994 May 15; 54(10):2527-30. PubMed ID: 8168072
    [Abstract] [Full Text] [Related]

  • 17. LEA-135 expression: its association with a lower risk of recurrence and increased overall survival of patients with lymph node-positive primary invasive breast cancer.
    Saha B, Zhang N, Naritoku WY, Tsao-Wei DD, Groshen SL, Carlsson G, Larsson L, Gustavsson B, Chaiwun B, Taylor CR, Imam SA.
    Anticancer Res; 2004 May 15; 24(4):2391-400. PubMed ID: 15330189
    [Abstract] [Full Text] [Related]

  • 18. The complex between urokinase and its type-1 inhibitor in primary breast cancer: relation to survival.
    Pedersen AN, Christensen IJ, Stephens RW, Briand P, Mouridsen HT, Danø K, Brünner N.
    Cancer Res; 2000 Dec 15; 60(24):6927-34. PubMed ID: 11156392
    [Abstract] [Full Text] [Related]

  • 19. Increased expression of urokinase-type plasminogen activator mRNA determines adverse prognosis in ErbB2-positive primary breast cancer.
    Urban P, Vuaroqueaux V, Labuhn M, Delorenzi M, Wirapati P, Wight E, Senn HJ, Benz C, Eppenberger U, Eppenberger-Castori S.
    J Clin Oncol; 2006 Sep 10; 24(26):4245-53. PubMed ID: 16963728
    [Abstract] [Full Text] [Related]

  • 20. Urokinase-type plasminogen activator system in breast cancer: association with tamoxifen therapy in recurrent disease.
    Meijer-van Gelder ME, Look MP, Peters HA, Schmitt M, Brünner N, Harbeck N, Klijn JG, Foekens JA.
    Cancer Res; 2004 Jul 01; 64(13):4563-8. PubMed ID: 15231667
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.